NATSAR Pharmaceuticals

Natsar Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative small molecule therapies for the treatment of cancer. The company's lead candidate, NT-001, is a first-in-class inhibitor of glutaminase, an enzyme critical for the metabolic reprogramming of tumor cells. By targeting the mitochondrial metabolism of cancer cells, Natsar aims to disrupt the energy supply and biosynthetic pathways necessary for tumor growth. The company is currently evaluating NT-001 in Phase 1/2 clinical trials for patients with advanced solid tumors, including pancreatic and lung cancers. Natsar's research is grounded in the understanding of how metabolic vulnerabilities can be exploited to create more effective oncology treatments.